Denali Advisors LLC Lowers Stake in HCA Healthcare, Inc. $HCA

Key Points

• Denali Advisors LLC has reduced its stake in HCA Healthcare by 48.0%, now holding 1,300 shares valued at approximately $498,000.
• HCA Healthcare reported $6.84 earnings per share for the last quarter, surpassing analyst expectations and showing a revenue increase of 6.4% year-over-year.
• Insider Michael S. Cuffe sold 3,836 shares of HCA at an average price of $418.84, resulting in a transaction worth over $1.6 million and a 10.85% decrease in his ownership.

Denali Advisors LLC reduced its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 48.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 1,300 shares of the company's stock after selling 1,200 shares during the period. Denali Advisors LLC's holdings in HCA Healthcare were worth $498,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Cookson Peirce & Co. Inc. acquired a new stake in shares of HCA Healthcare in the 2nd quarter worth $239,000. Greenup Street Wealth Management LLC lifted its stake in shares of HCA Healthcare by 1.5% in the 2nd quarter. Greenup Street Wealth Management LLC now owns 6,231 shares of the company's stock worth $2,387,000 after acquiring an additional 90 shares during the period. Maj Invest Holding A S lifted its stake in shares of HCA Healthcare by 0.4% in the 2nd quarter. Maj Invest Holding A S now owns 319,050 shares of the company's stock worth $122,228,000 after acquiring an additional 1,224 shares during the period. Avidian Wealth Enterprises LLC lifted its stake in shares of HCA Healthcare by 12.4% in the second quarter. Avidian Wealth Enterprises LLC now owns 786 shares of the company's stock valued at $301,000 after purchasing an additional 87 shares during the period. Finally, DekaBank Deutsche Girozentrale lifted its stake in shares of HCA Healthcare by 2.4% in the second quarter. DekaBank Deutsche Girozentrale now owns 98,819 shares of the company's stock valued at $37,318,000 after purchasing an additional 2,313 shares during the period. 62.73% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at HCA Healthcare

In other HCA Healthcare news, EVP Michael S. Cuffe sold 3,836 shares of the business's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the completion of the sale, the executive vice president directly owned 31,503 shares in the company, valued at $13,194,716.52. The trade was a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

HCA Healthcare Stock Performance

HCA Healthcare stock opened at $441.08 on Thursday. HCA Healthcare, Inc. has a 1 year low of $289.98 and a 1 year high of $443.41. The firm has a 50 day moving average price of $412.90 and a 200 day moving average price of $380.12. The company has a market cap of $103.21 billion, a price-to-earnings ratio of 18.54, a PEG ratio of 1.37 and a beta of 1.40.

HCA Healthcare (NYSE:HCA - Get Free Report) last released its earnings results on Friday, July 25th. The company reported $6.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.20 by $0.64. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. The firm had revenue of $18.61 billion during the quarter, compared to the consensus estimate of $18.49 billion. During the same period in the previous year, the firm earned $5.50 earnings per share. HCA Healthcare's revenue was up 6.4% compared to the same quarter last year. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. Sell-side analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Tuesday, September 16th were paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 0.7%. The ex-dividend date was Tuesday, September 16th. HCA Healthcare's payout ratio is currently 12.11%.

Analysts Set New Price Targets

Several analysts recently commented on HCA shares. Wall Street Zen upgraded shares of HCA Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Truist Financial set a $460.00 target price on shares of HCA Healthcare in a research report on Tuesday, October 14th. Royal Bank Of Canada cut their target price on shares of HCA Healthcare from $404.00 to $401.00 and set an "outperform" rating for the company in a research report on Monday, July 28th. Cantor Fitzgerald restated an "overweight" rating and set a $444.00 target price on shares of HCA Healthcare in a research report on Tuesday, October 7th. Finally, The Goldman Sachs Group assumed coverage on shares of HCA Healthcare in a report on Tuesday, October 14th. They set a "buy" rating and a $470.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat.com, HCA Healthcare currently has an average rating of "Moderate Buy" and a consensus target price of $437.19.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.